Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Durie BGM, Kyle RA, et al. Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation. Hematol J. 2003; 4: 379–98.
Durie BGM, Jacobson J, et al. Magnitude of response with myeloma frontline therapy does not predict outcome: importance of time to progression in Southwest Oncology Group chemotherapy trials. J Clin Oncol. 2004; 22(10): 1857–63.
Durie BGM, Salmon SE. A clinical staging system for multiple myeloma. Cancer 1975; 36: 842–854.
Gahrton G, Durie BGM, et al. Multiple Myeloma and Related Disorders, The role of imaging in myeloma. Arnold 2004; 10: 155–63.
Greipp PR, Durie BGM, et al. International sStaging sSystem for multiple myeloma. J Clin Oncol. 2005; 23(15): 3412–20.
Kyle RA, Schreiman JS, et al. Computer tomography in diagnosis and management of multiple myeloma and its variants. Arch Intern Med. 1985; 145: 1451–2.
Antoch G, Vogt FM, Freudenberg LS, et al. Whole-body dual-modality PET/CT and whole-body MRI for tumor staging in oncology. JAMA 2003; 290: 3199–206.
Modic MT, Obuchowski N. Whole-body CT screening for cancer and coronary disease: does it pass the test? Cleveland Clin J Med 2004; 71(1): 47–56.
Durie BGM, Waxman AD, et al. Whole Body F-FDG PET identifies high-risk myeloma. J Nucl Med. 2002; 43: 1457–63.
Bauer A, Stabler A, et al. Magnetic resonance imaging as a supplement for the clinical staging system of Durie and Salmon? Cancer. 2002; 95(6): 1334–5.
Walker R, Jones-Jackson L, et al. Diagnostic imaging of multiple myeloma-–FDG PET and MRI complementary for tracking short vs long term tumor response [abstract #758]. Blood. 2004; 104(11): 217a.
Kusumoto S, Jinnai I, Itoh K, et al. Magnetic resonance imaging patterns in patients with multiple myeloma. Br J of Haematol. 1997; 99: 649–655.
Mariette X, Zagdanski AM, Guermazi A, et al. Prognostic value of vertebral sessions detected by magnetic resonance imaging in patients with stage I multiple myeloma. Br J of Haematol. 1999; 104: 723–729.
Walker R, Barlogie B, et al. Prospective evaluation of 460 patients from total therapy II - —identification of characteristics on baseline MRI examinations of prognostic significance - —importance of focal lesions (FL) in multiple myeloma (MM). Hematol J. 2003; 4: S171. Abstract 188.
Schirmeister H, Bommer M, et al. Initial results in the assessment of multiple myeloma using 18 F-FDG PET. Eur J Nucl Med. 2002; 29: 361–6.
Walker RC, Barlogie B, Shaughnessy J. DKK1 in myeloma: correlation with FDG-PET. New Engl J Med. 2004; 350(14): 1465–6.
Miceli M, Atoui R, Walker R, et al. Diagnosis of deep septic thrombophlebitis in cancer patients by fluorine-18 flurodeoxyglucose positron emission tomography scanning: a preliminary report. J Clin Oncol. 2004; 22(10): 1949–56.
Mileshkin L, Blum R, Seymour JF, et al. A comparison of fluorine-18 fluoro-deox-yglucose PET and technetium-99m sestamibi in assessing patients with multiple myeloma. Europ J Haematol. 2004; 72(1): 32–7.
Fonti R, Vecchio S, Zannetti A, et al. Functional imaging of multidrug resistant pheno-type by 99mTcMIBI scan in patients with multiple myeloma. 2004; 19(2): 165–70.
Durie BGM, et al. Technetium-99m-MIBI scanning in multiple myeloma (MM): comparison with PET (FDG) imaging. Blood 1996; 88: 10. Abstract 1559.
Tirovola EB, Biassoni L, Britton KE, et al. The use of 99mTc-MIBI scanning in multiple myeloma. Br J Cancer. 1996; 74: 1815–20.
Durie BGM, Waxman AD, D'Agnolo A. A whole-body Tc-99m-MIBI scanning in the evaluation of multiple myeloma (MM). J Nucl Med. 1998; 39: 138.
Jaksic W, Trudel S, Chang H, et al. Clinical outcomes in t(4;14) multiple myeloma: a chemotherapy-sensitive disease characterized by rapid relapse and alkylating agent resistance. J Clin Oncol. 2005; 23(28): 7069–73.
Dewald GW, Therneau T, et al. Relationship of patient survival and chromosome anomalies detected in metaphase and/or interphase cells at diagnosis of myeloma. Blood. 2005; 106(10): 3553–8.
Terpos E, Szydlo R, Apperley JF, et al. Soluble receptor activator of nuclear factor kB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index. Blood. 2003; 102(3): 1064–9.
Chim CS, Ooi GC, et al. Unusual presentations of hematologic malignancies: role of MRI and FDG-PET in evaluation of solitary plasmacytoma. J Clinic Oncol. 2004; 22(7): 1328–30.
Durie BGM. The roll of anatomic and functional staging in myeloma: Description description of Durie/Salmon plus staging system. European J of Cancer. 2006; 42:1539–43.
Hillner BE, et al. Clinical decisions associated with positron emission tomography in a prospective cohort of patients with suspected or known cancer at one United States center. J Clinic Oncol. 2004; 22(20):4147–56.
Walker R, Barlogie B, et al. Magnetic resonance imaging in multiple myeloma: Diagnostic diagnostic and clinical implications. J Clinic Oncol. 25(9):1121–28.
Thomsen HS. Nephrogenic systemic fibrosis: A serious late adverse reaction to gadodiamide. Eur Radiol. 2006; 16:2619–2621.
Moran GR, Pekar J, Bartolini M, et al. An Investigation of the toxicity of gadolinium based MRI contrast agents. Proc Intl Soc Mag Reson Med. 2002. 10.
Swaminathan S, Horn T, Pellowski, et al. Nephrogenic systemic fibrosis, gadolinium, and iron mobilization. N Engl J Med. 2007; 357(7): 720–722.
Hillner BE, Siegel BA, Liu D, et al. Impact of positron emission tomography/computed tomography and positron emission tomography (PET) alone on expected management of patients with cancer: Initial results from the national oncologic PET registry. J Clin Onco. 2008; 26(13). (Published ahead of print.)
Salaun P-Y, Gastinne T, Frampas E, et al. FDG-positron-emission tomography for staging and therapeutic assessment in patients with plasmacytoma. Haematologica. 2008; 93(8):1269–1271.
Patel RR, Subramaniam RM, Mandrekar JN. Occult malignancy in patients with suspected paraneoplastic neurologic syndromes: value of positron emission tomography in diagnosis. Mayo Clin Proc. 2008; 83(8):917–922.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2008 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Durie, B.G. (2008). The Role of Anatomic and Functional Imaging in Myeloma. In: Lonial, S. (eds) Myeloma Therapy. Contemporary Hematology. Humana Press. https://doi.org/10.1007/978-1-59745-564-0_30
Download citation
DOI: https://doi.org/10.1007/978-1-59745-564-0_30
Publisher Name: Humana Press
Print ISBN: 978-1-934115-82-4
Online ISBN: 978-1-59745-564-0
eBook Packages: MedicineMedicine (R0)